SCHEMBL2883584

SCHEMBL2883584

CS(=O)(=O)Nc1ccccc1N1CCN(c2nc3cnc(-c4ccccc4)nc3[nH]2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 2/20 0.40
ALDH1A1 P00352 6/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
MCOLN2 Q8IZK6 1/20 0.38
MCOLN3 Q8TDD5 1/20 0.38
MCOLN1 Q9GZU1 1/20 0.38
HSP90AB1 P08238 1/20 0.36
CYP1A2 P05177 3/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2D6 P10635 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
HTR2B P41595 1/20 0.36
KDM4E B2RXH2 2/20 0.36
MEN1 O00255 1/20 0.36
CYP2C19 P33261 1/20 0.36
KMT2A Q03164 1/20 0.36
TSHR P16473 1/20 0.36
HTR3A P46098 1/20 0.35
MAPK1 P28482 2/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2883586 0.85 NPY5R (0.39) NPY5RALDH1A1L3MBTL1MCOLN2MCOLN3
SCHEMBL14355835 0.69 TSHR (0.52) ALDH1A1MCOLN2MCOLN3MCOLN1HSP90AB1
SCHEMBL2884249 0.68 ADRB1 (0.53) MCOLN2MCOLN3MCOLN1CYP1A2CYP2D6
SCHEMBL23043705 0.67 MCOLN3 (0.61) ALDH1A1L3MBTL1MCOLN2MCOLN3MCOLN1
SCHEMBL4524859 0.67 NPY5R (0.52) NPY5RALDH1A1MCOLN2MCOLN3MCOLN1
SCHEMBL2884465 0.67 NPY5R (0.51) NPY5RHTR2BHTR3A
Hydrochloric Acid SCHEMBL4524195 0.67 ADRB1 (0.51) ALDH1A1MCOLN2MCOLN3MCOLN1KDM4E
SCHEMBL4513143 0.65 MAPT (0.52) L3MBTL1MCOLN2MCOLN3MCOLN1HSP90AB1
SCHEMBL2884475 0.63 HTR2B (0.40) NPY5RALDH1A1L3MBTL1NPSR1HTR2B
SCHEMBL2879069 0.63 HTR2B (0.40) NPY5RALDH1A1L3MBTL1NPSR1HTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691860-B2 Sulfonamide derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-04-06 US claimed
US-20080161326-A1 Novel Sulfone Amide Amide Derivatives MSD K.K. (JP) 2008-07-03 US claimed
EP-1719765-A1 NOVEL SULFONE AMIDE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-08 EP claimed
US-7691860-B2 Sulfonamide derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-04-06 US disclosed
US-20080161326-A1 Novel Sulfone Amide Amide Derivatives MSD K.K. (JP) 2008-07-03 US disclosed
EP-1719765-A1 NOVEL SULFONE AMIDE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161326-A1 Novel Sulfone Amide Amide Derivatives NPY1R, NPY2R, NPY5R NPY5R 3/4885ALDH1A1 1680/4885L3MBTL1 2917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.